Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3855 Target Snapshot

UDP-3-O-acyl-N-acetylglucosamine deacetylase · SINGLE PROTEIN · Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)

651Compounds
23Assays
0Approved Drugs
603.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt P47205. Use UniProt P47205 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt P47205 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats UDP-3-O-acyl-N-acetylglucosamine deacetylase as ChEMBL target CHEMBL3855, mapped to UniProt P47205. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
UDP-3-O-acyl-N-acetylglucosamine deacetylase
SINGLE PROTEIN · Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)
As of 2026-09-14
ChEMBL target ID
CHEMBL3855
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P47205
UDP-3-O-acyl-N-acetylglucosamine deacetylase
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether UDP-3-O-acyl-N-acetylglucosamine deacetylase is the right protein anchor across sources, using UniProt P47205 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelUDP-3-O-acyl-N-acetylglucosamine deacetylase
UniProt AccessionP47205
Component TypeProtein
Sequence Length303 aa

UDP-3-O-acyl-N-acetylglucosamine deacetylase

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as UDP-3-O-acyl-N-acetylglucosamine deacetylase, mapped to UniProt P47205. Sequence length is 303 aa.

Mapped IDP47205
Review nameUDP-3-O-acyl-N-acetylglucosamine deacetylase
OrganismPseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG12228)
Clinical Profile

Clinical Phase Distribution

1
Phase I
Assay Mix

Activity Type Distribution

IC50587.0
KD16.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3939284 10.7 IC50 0.02 Preclinical
CHEMBL4464418 10.59 Kd 0.026 Preclinical
CHEMBL3647134 10.52 IC50 0.0303 Preclinical
CHEMBL3904237 10.47 IC50 0.034 Preclinical
CHEMBL3647135 10.23 IC50 0.0592 Preclinical
CHEMBL4517452 10.2 Kd 0.063 Preclinical
CHEMBL4437188 10.19 Kd 0.065 Preclinical
CHEMBL3647088 10.17 IC50 0.0669 Preclinical
CHEMBL3917201 10.17 IC50 0.0674 Preclinical
CHEMBL1956145 10.07 IC50 0.0842 Preclinical
Distribution

pChEMBL Value Distribution

36
5.0
20
5.5
17
6.0
19
6.5
26
7.0
59
7.5
112
8.0
73
8.5
72
9.0
43
9.5
pChEMBL
Assay Landscape

Assay Landscape

23
Total Assays
514
Tested Compounds
1
Assay Types
Binding — 23 assays, 514 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 12 190 7.1
single protein format 10 324 8.1
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine